Influenza A virus H1N1 vaccine - CPL Biologicals

Drug Profile

Influenza A virus H1N1 vaccine - CPL Biologicals

Alternative Names: CadiFlu; H1N1 influenza VLP vaccine - Novavax; H1N1 virus-like particle pandemic influenza vaccine - Novavax; Monovalent influenza A (H1N1 2009) virus like particle (VLP) vaccine - CPL Biologicals; Swine flu vaccine - Novavax; Unadjuvanted 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine - Novavax

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novavax
  • Developer CPL Biologicals; Novavax
  • Class Influenza A virus H1N1 vaccines; Influenza virus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 31 Dec 2012 CPL Biologicals initiates a phase I trial of its Influenza-A virus H1N1 subtype vaccine in India
  • 04 Aug 2011 Final immunogenicity data from a phase II trial in Influenza-A virus H1N1 subtype (Prevention) released by Novavax
  • 01 Mar 2011 Novavax receives a contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of Influenza virus-like particle vaccines in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top